Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel. (Q53989176)

23 May 2018

title

Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel. (English)

1 reference

23 May 2018

0 references

1

1 reference

23 May 2018

author name string

P Nisipeanu

series ordinal

2

1 reference

23 May 2018

publication date

1 April 1996

1 reference

23 May 2018

published in

Journal of Neurology

1 reference

23 May 2018

volume

243

1 reference

23 May 2018

issue

4 Suppl 1

1 reference

23 May 2018

page(s)

S23-6

1 reference

23 May 2018

https://scigraph.springernature.com/pub.10.1007/bf00873698

exact match

0 references

cites work

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF00873698

Therapy for multiple sclerosis.

21 January 2018

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report

1 reference

12 December 2020

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

1 reference

12 December 2020

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

12 December 2020

Copolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

1 reference

12 December 2020

Options for multiple sclerosis therapy

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00873698

1 reference

23 May 2018

release_zixi2sc62baxde47nyhpgkndwu

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zixi2sc62baxde47nyhpgkndwu

24 November 2022

mapped directly with Wikidata item

PubMed ID

8965117

1 reference

23 May 2018